These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34899631)

  • 21. CRISPR-Cas13d mediates robust RNA virus interference in plants.
    Mahas A; Aman R; Mahfouz M
    Genome Biol; 2019 Dec; 20(1):263. PubMed ID: 31791381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the application of CRISPR-Cas technology in rapid detection of pathogen nucleic acid.
    Li X; Zhong J; Li H; Qiao Y; Mao X; Fan H; Zhong Y; Imani S; Zheng S; Li J
    Front Mol Biosci; 2023; 10():1260883. PubMed ID: 37808520
    [No Abstract]   [Full Text] [Related]  

  • 23. Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.
    Koonin EV; Gootenberg JS; Abudayyeh OO
    Biochemistry; 2023 Dec; 62(24):3465-3487. PubMed ID: 37192099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress of CRISPR-based programmable RNA manipulation and detection.
    Wang B; Yang H
    Wiley Interdiscip Rev RNA; 2023; 14(6):e1804. PubMed ID: 37282821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications of the versatile CRISPR-Cas13 RNA targeting system.
    Kordyś M; Sen R; Warkocki Z
    Wiley Interdiscip Rev RNA; 2022 May; 13(3):e1694. PubMed ID: 34553495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular architectures and mechanisms of Class 2 CRISPR-associated nucleases.
    Garcia-Doval C; Jinek M
    Curr Opin Struct Biol; 2017 Dec; 47():157-166. PubMed ID: 29107822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cas4 Nucleases Can Effect Specific Integration of CRISPR Spacers.
    Zhang Z; Pan S; Liu T; Li Y; Peng N
    J Bacteriol; 2019 Jun; 201(12):. PubMed ID: 30936372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR/Cas systems for the detection of nucleic acid and non-nucleic acid targets.
    Su W; Li J; Ji C; Chen C; Wang Y; Dai H; Li F; Liu P
    Nano Res; 2023 Mar; ():1-14. PubMed ID: 37359078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Versatile Type V CRISPR Effectors and Their Application Prospects.
    Tong B; Dong H; Cui Y; Jiang P; Jin Z; Zhang D
    Front Cell Dev Biol; 2020; 8():622103. PubMed ID: 33614630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in structural studies of the CRISPR-Cas-mediated genome editing tools.
    Zhu Y; Huang Z
    Natl Sci Rev; 2019 May; 6(3):438-451. PubMed ID: 34691893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas adaptation in Escherichia coli.
    Mitić D; Bolt EL; Ivančić-Baće I
    Biosci Rep; 2023 Mar; 43(3):. PubMed ID: 36809461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral diversity threshold for adaptive immunity in prokaryotes.
    Weinberger AD; Wolf YI; Lobkovsky AE; Gilmore MS; Koonin EV
    mBio; 2012 Dec; 3(6):e00456-12. PubMed ID: 23221803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structures and mechanisms of CRISPR RNA-guided effector nucleases.
    Nishimasu H; Nureki O
    Curr Opin Struct Biol; 2017 Apr; 43():68-78. PubMed ID: 27912110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and application of sensitive, specific, and rapid CRISPR-Cas13-based diagnosis.
    Shihong Gao D; Zhu X; Lu B
    J Med Virol; 2021 Jul; 93(7):4198-4204. PubMed ID: 33599292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmable Inhibition and Detection of RNA Viruses Using Cas13.
    Freije CA; Myhrvold C; Boehm CK; Lin AE; Welch NL; Carter A; Metsky HC; Luo CY; Abudayyeh OO; Gootenberg JS; Yozwiak NL; Zhang F; Sabeti PC
    Mol Cell; 2019 Dec; 76(5):826-837.e11. PubMed ID: 31607545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-Cas System: The Powerful Modulator of Accessory Genomes in Prokaryotes.
    Butiuc-Keul A; Farkas A; Carpa R; Iordache D
    Microb Physiol; 2022; 32(1-2):2-17. PubMed ID: 34192695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Cas systems and RNA-guided interference.
    Barrangou R
    Wiley Interdiscip Rev RNA; 2013; 4(3):267-78. PubMed ID: 23520078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR technology to combat plant RNA viruses: A theoretical model for Potato virus Y (PVY) resistance.
    Hameed A; Shan-E-Ali Zaidi S; Sattar MN; Iqbal Z; Tahir MN
    Microb Pathog; 2019 Aug; 133():103551. PubMed ID: 31125685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy.
    Elliott EK; Haupt LM; Griffiths LR
    Transgenic Res; 2021 Apr; 30(2):129-141. PubMed ID: 33609253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action.
    Makarova KS; Grishin NV; Shabalina SA; Wolf YI; Koonin EV
    Biol Direct; 2006 Mar; 1():7. PubMed ID: 16545108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.